The estimated Net Worth of Andrew Sinclair is at least $876 million dollars as of 29 March 2022. Mr. Sinclair owns over 7,720,000 units of Soleno Therapeutics Inc stock worth over $875,538,005 and over the last 6 years he sold SLNO stock worth over $0. In addition, he makes $20,050 as Independent Director at Soleno Therapeutics Inc.
Sign up
Mr. Sinclair SLNO stock SEC Form 4 insiders trading
Andrew has made over 6 trades of the Soleno Therapeutics Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he bought 7,720,000 units of SLNO stock worth $375,037,600 on 29 March 2022.
The largest trade he's ever made was buying 7,720,000 units of Soleno Therapeutics Inc stock on 29 March 2022 worth over $375,037,600. On average, Andrew trades about 1,142,094 units every 60 days since 2018. As of 29 March 2022 he still owns at least 18,022,602 units of Soleno Therapeutics Inc stock.
You can see the complete history of Mr. Sinclair stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Andrew Sinclair biography
Andrew Sinclair Ph.D. serves as Independent Director of the Company. Dr. Sinclair has held various positions at Abingworth LLP, a life sciences investment group, where he is currently a Partner and Portfolio Manager. Dr. Sinclair currently sits on the board of Verona Pharma plc and is a member of the Institute of Chartered Accountants in England.
What is the salary of Andrew Sinclair?
As the Independent Director of Soleno Therapeutics Inc, the total compensation of Andrew Sinclair at Soleno Therapeutics Inc is $20,050. There are 9 executives at Soleno Therapeutics Inc getting paid more, with Anish Bhatnagar having the highest compensation of $822,089.
How old is Andrew Sinclair?
Andrew Sinclair is 48, he's been the Independent Director of Soleno Therapeutics Inc since 2019. There are 10 older and no younger executives at Soleno Therapeutics Inc. The oldest executive at Soleno Therapeutics Inc is Ernest Mario, 81, who is the Independent Chairman of the Board.
What's Andrew Sinclair's mailing address?
Andrew's mailing address filed with the SEC is 203 REDWOOD SHORES PKWY, STE 500, , REDWOOD CITY, CA, 94065.
Insiders trading at Soleno Therapeutics Inc
Over the last 9 years, insiders at Soleno Therapeutics Inc have traded over $134,327,999 worth of Soleno Therapeutics Inc stock and bought 56,592,152 units worth $70,324,676 . The most active insiders traders include Advisors Llcperceptive Life..., Jack W Schuler et Andrew Sinclair. On average, Soleno Therapeutics Inc executives and independent directors trade stock every 29 days with the average trade being worth of $36,911,570. The most recent stock trade was executed by Kristen Yen on 28 August 2024, trading 10,705 units of SLNO stock currently worth $507,738.
What does Soleno Therapeutics Inc do?
soleno therapeutics, inc. is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. the company is currently advancing its lead candidate, dccr, a once-daily oral tablet for the treatment of pws, into a phase iii clinical development program in early 2018.
What does Soleno Therapeutics Inc's logo look like?
Complete history of Mr. Sinclair stock trades at Sierra Oncology Inc, Soleno Therapeutics Inc et Verona Pharma Plc
Soleno Therapeutics Inc executives and stock owners
Soleno Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Anish Bhatnagar,
President, Chief Executive Officer, Director -
Dr. Anish Bhatnagar,
Pres, CEO, COO & Director -
Patricia Hirano,
Vice President - Regulatory Affairs -
Kristen Yen,
Vice President - Clinical Operations -
James H. MacKaness,
Chief Financial Officer -
Ernest Mario,
Independent Chairman of the Board -
William Harris,
Independent Director -
Gwen Melincoff,
Independent Director -
Birgitte Volck,
Independent Director -
Andrew Sinclair,
Independent Director -
Dr. Neil M. Cowen M.B.A., Ph.D., MBA,
Sr. VP of Drug Devel. -
Anthony Wondka,
Sr. VP & GM -
Dawn Carter Bir,
-
Jack W Schuler,
-
Larry N Feinberg,
10% owner -
Opportunity, Llc Vivo Oppor...,
-
Jonathan Wolter,
Chief Financial Officer -
Stephen Kirnon,
Director -
Mahendra Shah,
Director -
Rajen Dalal,
Director -
Edgar Engleman,
Director -
Ventures V, Llc Vivo,
10% owner -
Steinar J Engelsen,
Director -
James Walter Glasheen,
Director -
Stuart J Collinson,
Director -
Ventures V, Llc Vivo Ventur...,
-
Raymond W. Urbanski,
CHIEF DEVELOPMENT OFFICER -
Management Vii Llctechnolog...,
-
Mangement Llcbioasia Invest...,
-
Larry Noracle Partners Lp F...,
-
Llp Abingworth,
10% owner -
Ventures V, Llc Vivo Ventur...,
-
Group Inc.Carlyle Holdings ...,
-
Meredith Manning,
Chief Commercial Officer -
Michael F. Huang,
Sr. VP of Clinical Development -
Matthew Pauls,
-
Group Inc.Carlyle Holdings ...,
-
Advisors Llcperceptive Life...,
-
James H Mackaness,
CHIEF FINANCIAL OFFICER